Melanotan-2 vs PT-141
The table compares the compounds’ key data from their entry pages. Open each compound’s full entry for details. Educational content, not medical advice.
Melanotan-2 | PT-141 | |
|---|---|---|
| What it is | Experimental tan-boosting peptide that also acts on libido and appetite; few studies in humans so far. | Approved medicine for low sexual desire disorder in women before menopause, acting through the nervous system. |
| Type | Cyclic heptapeptide (MC1-5R agonist) | Melanocortin receptor agonist (MC3R/MC4R) |
| Structure | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Molecular weight | ~1024 Da | ~1025 Da |
| Target area | Skin pigmentation, libido | Disorder of reduced sexual desire |
| Storage | 2–8°C (reconstituted) | 2–8°C (reconstituted) |
| Stability | 25–30 days (reconstituted) | 25–30 days (reconstituted) |
| Full entry | Open → | Open → |
Melanotan-2 or PT-141: what is the difference?
The two peptides are almost the same: their structures differ only at the very end of the chain. Melanotan-2 switches on several melanocortin receptors, so it affects tanning, sexual desire and appetite; the PT-141 entry names two receptors (MC3R, MC4R), and its target is low sexual desire disorder. PT-141 was in fact developed because Melanotan-2 also affected sexual desire as a side effect. The biggest difference is their status: Melanotan-2 is an experimental compound with only a few small human studies, while PT-141 was approved by the FDA in 2019 as Vyleesi, for low sexual desire in premenopausal women.

